Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  Issue: January 2022  |  

References

  1. Ytterberg S, Bhatt D, Mikuls T, et al. Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: Results from a Phase 3b/4 randomized safety trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  2. Charles-Schoeman C, Buch M, Dougados M, et al. Risk factors for major adverse cardiovascular events in patients aged ≥50 years with RA and ≥1 additional cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  3. Curtis J, Yamaoka K, Chen Y, et al. Malignancies in patients aged ≥50 years with RA and ≥1 additional cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  4. Charles-Schoeman C, Fleischmann R, Mysler E, et al. The risk of venous thromboembolic events in patients with RA aged ≥ 50 years with ≥ 1 cardiovascular risk factor: Results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors Arthritis Rheumatol. 2021;73(suppl 10).
  5. Hahn J, Cook N, Alexander A, et al. Vitamin D and marine n-3 fatty acid supplementation and prevention of autoimmune disease in the VITAL randomized controlled trial Arthritis Rheumatol. 2021;73(suppl 10).
  6. Rech J, Ostergaard M, Tascilar K, et al. Abatacept reverses subclinical arthritis in patients with high-risk to develop rheumatoid arthritis—Results from the randomized, placebo-controlled ARIAA study in RA-at risk patients Arthritis Rheumatol. 2021;73(suppl 10).
  7. Colmegna I, Useche M, Rampakakis E, et al. COVID-19 vaccine in immunosuppressed adults with autoimmune diseases [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  8. Mahil S, Bechman K, Raharja A, et al. Humoral and cellular immune responses to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: A cohort study [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  9. Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: A randomized controlled trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  10. Solomon J, Woodhead F, Danoff S, et al. A randomized, double-blinded, placebo-controlled, phase 2 study of safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis interstitial lung disease [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  11. Najm A, Sarda S, Toro M, et al. B cells repertoire repartition predicts response to methotrexate at 6 and 12 months in naïve RA: A machine learning driven approach [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).

Related Articles
    ACR Convergence 2020

    ACR Convergence 2020: Progress Toward COVID-19 Vaccines

    ACR CONVERGENCE 2020—A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across…

    Space & Other Races

    On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEThis group of scientists met to discuss…